Authors: Andrew V Uzilov, Patricia Taik, Khadeen C Cheesman, Pedram Javanmard, Kai Ying, Alessia Roehnelt, Huan Wang, Marc Y Fink, Chun Yee Lau, Aye S Moe, Joaquin Villar, Joshua B Bederson, Andrew F Stewart, Michael J Donovan, Milind Mahajan, Robert Sebra, Kalmon D Post, Rong Chen, Eliza B Geer
Context: Pituitary corticotroph adenomas are rare tumors that can be associated with excess adrenocorticotropin (ACTH) and adrenal cortisol production, resulting in the clinically debilitating endocrine condition Cushing disease. A subset of corticotroph tumors behave aggressively, and genomic drivers behind the development of these tumors are largely unknown.
Objective: To investigate genomic drivers of corticotroph tumors at risk for aggressive behavior.
Design: Whole-exome sequencing of patient-matched corticotroph tumor and normal deoxyribonucleic acid (DNA) from a patient cohort enriched for tumors at risk for aggressive behavior.
Setting: Tertiary care center.
Patients: Twenty-seven corticotroph tumors from 22 patients were analyzed. Twelve tumors were macroadenomas, of which 6 were silent ACTH tumors, 2 were Crooke’s cell tumors, and 1 was a corticotroph carcinoma.
Intervention: Whole-exome sequencing.
Main outcome measure: Somatic mutation genomic biomarkers.
Results: We found recurrent somatic mutations in USP8 and TP53 genes, both with higher allelic fractions than other somatic mutations. These mutations were mutually exclusive, with TP53 mutations occurring only in USP8 wildtype (WT) tumors, indicating they may be independent driver genes. USP8-WT tumors were characterized by extensive somatic copy number variation compared with USP8-mutated tumors. Independent of molecular driver status, we found an association between invasiveness, macroadenomas, and aneuploidy.
Conclusions: Our data suggest that corticotroph tumors may be categorized into a USP8-mutated, genome-stable subtype versus a USP8-WT, genome-disrupted subtype, the latter of which has a TP53-mutated subtype with high level of chromosome instability. These findings could help identify high risk corticotroph tumors, namely those with widespread CNV, that may need closer monitoring and more aggressive treatment.
Read the full publication here